Literature DB >> 22314698

Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-κB pathway in HT-29 cells.

Li Hou1, Bo Xu, Wei Guo, Fu-Xiang Ran, Jing-Tao Liu, Xia Yuan, Hong-Zheng Fu, Jing-Rong Cui.   

Abstract

PURPOSE: Pseudolaric acid B (PAB) is a diterpene acid isolated from the root and trunk bark of Pseudolaric kaempferi Gordon. Previous work has found that PAB has anti-inflammatory and anti-tumor effects in xenograft models of human hepatocellular carcinoma. The aim of this study is to evaluate the correlation between anti-cancer and anti-inflammatory effects of PAB and its molecular mechanisms on HT-29 cells.
METHODS: Production of prostaglandin E2 (PGE2) in HT-29 cells was evaluated by ELISA. mRNA of cyclooxygenase-2 (COX-2) was analyzed by RT-PCR assay. High-content screening (HCS) method was adopted to detect the cytokine mixture (CM)-induced transcription activity of NF-κB and STAT3. Western blotting was used to evaluate the protein expression levels of inflammatory mediators induced by CM. After treatment with PAB in various concentrations, the inhibition rate of cell proliferation was measured with sulforhodamine B assays. For the in vivo studies, tumor-bearing models xenografted with HT-29 cells were developed in nude mice, and following oral administration with PAB, tumor inhibition rate was calculated.
RESULTS: PAB inhibited the PGE2 production in HT-29 cells significantly (P < 0.05) with similar results detected at the COX-2 mRNA level. Furthermore, PAB suppressed the COX-2 protein expression and significant nuclear translocation of NF-κB and STAT3 induced by CM, which correlated with a concomitant degradation of I-κB and a decrease in constitutive STAT3 phosphorylation (P < 0.05). Moreover, various concentrations of PAB inhibited the proliferation of HT-29 cells in a dose- and time-dependent manner. In vivo, after treatment with PAB for 17 days, the tumor weight of the 50 and 100 mg/kg treated groups was 0.62 ± 0.15 and 0.54 ± 0.06 g, respectively. When compared to the control group (0.82 ± 0.16 g), the inhibition rate of tumor weight was 24.2% at 50 mg/kg (P < 0.05) and 34.7% at 100 mg/kg (P < 0.001).
CONCLUSIONS: PAB shows potential anti-cancer activity in HT-29 cells, and its molecular mechanisms are related to the anti-inflammatory action.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22314698     DOI: 10.1007/s00432-011-1120-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

1.  The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid-A and -B and related derivatives.

Authors:  D J Pan; Z L Li; C Q Hu; K Chen; J J Chang; K H Lee
Journal:  Planta Med       Date:  1990-08       Impact factor: 3.352

2.  Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.

Authors:  Vincent K W Wong; Pauline Chiu; Stephen S M Chung; Larry M C Chow; Yun-Zhe Zhao; Burton B Yang; Ben C B Ko
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

Review 3.  Inflammation and colon cancer.

Authors:  Janos Terzić; Sergei Grivennikov; Eliad Karin; Michael Karin
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

4.  Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways.

Authors:  Olorunseun Olatunji Ogunwobi; Ian L P Beales
Journal:  Regul Pept       Date:  2005-09-19

5.  Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin.

Authors:  Yun-Guang Tong; Xiong-Wen Zhang; Mei-Yu Geng; Jian-Ming Yue; Xian-Liang Xin; Fang Tian; Xu Shen; Lin-Jiang Tong; Mei-Hong Li; Chao Zhang; Wei-Hong Li; Li-Ping Lin; Jian Ding
Journal:  Mol Pharmacol       Date:  2006-01-19       Impact factor: 4.436

6.  Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death.

Authors:  Xianfeng Gong; Minwei Wang; Shin-ichi Tashiro; Satoshi Onodera; Takashi Ikejima
Journal:  Exp Mol Med       Date:  2006-08-31       Impact factor: 8.718

7.  Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.

Authors:  Wen-Fu Tan; Xiong-Wen Zhang; Mei-Hong Li; Jian-Min Yue; Yi Chen; Li-Ping Lin; Jian Ding
Journal:  Eur J Pharmacol       Date:  2004-09-24       Impact factor: 4.432

Review 8.  Turning off signal transducer and activator of transcription (STAT): the negative regulation of STAT signaling.

Authors:  Weiguo Chen; Michael O Daines; Gurjit K Khurana Hershey
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 9.  Pro-inflammatory prostaglandins and progression of colorectal cancer.

Authors:  Dingzhi Wang; Raymond N DuBois
Journal:  Cancer Lett       Date:  2008-04-11       Impact factor: 8.679

Review 10.  Inflammation and colorectal cancer.

Authors:  Sarah Kraus; Nadir Arber
Journal:  Curr Opin Pharmacol       Date:  2009-07-07       Impact factor: 5.547

View more
  5 in total

1.  The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-α/P-gp pathway.

Authors:  Qian Sun; Yan Li
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

2.  Pseudolaric acid B attenuates atopic dermatitis-like skin lesions by inhibiting interleukin-17-induced inflammation.

Authors:  Zhen Yang; Meilun Liu; Wei Wang; Yiteng Wang; Bo Cao; Ying Gao; Hong Chen; Tan Li
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

Review 3.  A Systematic Review of the Immune-Regulating and Anticancer Activities of Pseudolaric Acid B.

Authors:  Mei-Lun Liu; Dan Sun; Tan Li; Hong Chen
Journal:  Front Pharmacol       Date:  2017-06-28       Impact factor: 5.810

Review 4.  High content screening for drug discovery from traditional Chinese medicine.

Authors:  Jing Wang; Ming-Yue Wu; Jie-Qiong Tan; Min Li; Jia-Hong Lu
Journal:  Chin Med       Date:  2019-02-28       Impact factor: 5.455

5.  YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways.

Authors:  Bingjie Xue; Wei Huang; Xia Yuan; Bo Xu; Yaxin Lou; Quan Zhou; Fuxiang Ran; Zemei Ge; Runtao Li; Jingrong Cui
Journal:  J Cancer       Date:  2015-02-06       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.